NanoString medulloblastoma group determination

Background:
The World Health Organization Classification of Tumours of the Central Nervous System recognizes genetically-defined medulloblastoma groups – WNT-activated, SHH-activated and non-WNT/non-SHH (groups 3 and 4). Combined morphological and molecular information provides optimal prognostic and predictive information to guide clinical management.

Purpose of test:
The test assigns a medulloblastoma molecular subgroup on the basis of the expression level of 22 medulloblastoma signature genes using NanoString nCounter technology.

Caveats:
RNA integrity and concentration must meet assay requirements. Low tumour content may result in an inaccurate result. A small proportion of cases cannot be classified into any of the four groups.

Proficiency testing:
Exchange with an overseas centre performing the same test.

Reference:
Northcott PA et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathologica 2012; 123: 615-626.